Clinical Trial Search

Primary: Difference in Basal Layer Keratinocytes Positive for Both Ki67 and Thymine Dimers — 21.5; 14.7 positive cells/1000 basal layer cells

Primary: Percent Change From Baseline in Microtopographic Profilometry Ra Values (Skin Roughness). — 3.62; 18.57 Percent change post-treatment — p=<0.0001

Primary: Number of Genes Upregulated or Downregulated as Assessed by RNA Sequencing (Older Group, Retinol Versus Placebo) — 23; 21 genes

Primary: Global Wrinkling - Change From Baseline to Week 12, Averaged Expert Grader Scores — 0.18; 0.30 Units on a scale — p=<0.001

Primary: Subject Satisfaction — 2.8 score on a scale

Primary: Overall Improvement in Periorbital Wrinkles and Rhytids Around the Eyes — 47; 50 percentage of participants improved

Primary: Change in Neck and Facial Wrinkles Using the Fitzpatrick Wrinkle Assessment — 74 percentage of participants

Primary: Number of Participants With Severity of Photodamage — 0; 0; 1; 0 Participants

Primary: Photographic Knee Laxity and Texture Evaluation — 1.87; 2.02 score on a scale

Primary: Prevalence of Sun Protection Practices — 0.30; 0.43; 0.35; 0.41 proportion of practices/day

Primary: Inter-rater Reliability of Assessment of Facial Lines Using the 4-Point Facial Wrinkle Scale (FWS-A) — 0.653; 0.637; 0.647; 0.654 Kappa statistics

Primary: Number of TLR4 Signaling Pathway Analytes With a Significant Change in Expression From Baseline (Pre-solar Stimulated Light Exposure to 1 and 24 Hours Post Exposure)…

Primary: Number of Genes With Significant Change in Gene Transcription — 188; 45 genes

Primary: Number of Participants With Effectiveness and Safety Success — 30; 41 participants

Primary: Change From Baseline in Overall Photodamage Score — 5.6; -0.8 score on a scale — p=<0.001

Primary: Change in Facial Wrinkles at 12 Weeks Post Final Treatment Compared to Baseline — -0.10 units on a scale

Primary: Changes to the Surface by Visual and Photographic Analysis. — 41 participants

Primary: Change From Baseline in Investigator Global Assessment (IGA) of Participant's Overall Facial Appearance at Week 24 — 6.04; 5.81; 0.6; 0.7 units on scale — p=0.358

Primary: Photographic Evaluation of Wrinkle Severity at Baseline — 5.25 score on a scale

Primary: Percentage of Participants With Photo-initiated Potential Sensitization Reaction — 0; 0; 0; 0 Participants

Primary: DNA Damage Level by Cyclobutane Pyrimidine Dimer (CPD) Measurement — 2.48; 2.18; 2.64; 1.14 Optical Density Units — p=0.003

Primary: Fitzpatrick Classification of Wrinkling and Degree of Elastosis. — 5.6; 5.56; 5.36; 5.32 Fitzpatrick Classification Scale

Primary: Changes in Putrescine Over 3 Months — 0.03; 1.45; 0.2 nmol/g skin

Primary: Photographic Evaluation of Wrinkle Severity at Baseline — 5.7 score on a scale

Primary: Principal Investigator's Assessment of Improvement at 12 Weeks Post-final Treatment (Physician's Global Assessment of Improvement=GAIS) — 1.04 score on a scale

Primary: Change in Wrinkles From Baseline to 12 Weeks Post-study Treatment Assessed by Blinded Photographic Evaluation Using 9-Point Fitzpatrick Wrinkle Scale

Primary: Median VAS Improvement Score as Assessed by Blinded Physician Reviewers — 1.5 units on a scale — p=<0.0001

Primary: Global Photodamage Severity — 4.8; 5.45 units on a scale

Primary: The Change From Baseline to 30 Days After the Last Treatment in the Number of Senile Purpura Lesions — -3.55; -.35 number of purpuric lesions

Primary: Influence of a Patient's Melanoma Diagnosis on the Survivor's and Broader Family's Skin Cancer Prevention Activity. — 24; 22; 2; 5 Participants